256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval
The Readout Loud
00:00
The FDA Approves a Biogen Treatment for ALS
Lilly's market cap is approaching Johnson and Johnson's, which is just crazy. FDA approved Kelsati for a rare form of ALS that's caused by a mutation in a gene called SAD1. The surrogate marker or the preliminary evidence that they used to approve this drug is a reduction in a protein called neurofilament light chain.
Transcript
Play full episode
